Daewoong Pharmaceutical Halts COVID-19 Treatment Trials: "Low Severity in Omicron Cases"
[Asia Economy Reporter Choi Dae-yeol] Daewoong Pharmaceutical announced on the 18th that it will suspend domestic clinical trials of Camostat Mesylate (DWJ1248), which is being developed as a COVID-19 treatment. The company added that the need for development has decreased due to the lower severity rate caused by the spread of the Omicron variant.
Hot Picks Today
![[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"](https://cwcontent.asiae.co.kr/asiaresize/93/2026052014513970767_1779256299.png)
[Breaking] Samsung Electronics Management: "The Principle That Rewards Are Given Where There Are Results Has Been Upheld"
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
- "Was It You Again?" Elementary Student Involved in Last Week's Vehicle Theft Drives Off Himself This Time
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![[Breaking] Samsung Electronics Labor and Management Officially Sign Tentative Agreement](https://cwcontent.asiae.co.kr/asiaresize/307/2026052022492353201A.jpg)
